Last week, Sandoz announced they are closing a number of generic product development centers around the world, including the Sandoz Development Centre near Mumbai. A few items in this report…
At Lacerta Bio, we're in the middle of several international out-licensing projects. This process is enabling us to re-connect with many companies around the world. In addition, we're making new…
Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will…
Call us late to the party, but in August of this year, KPMG published Future Pharma: Five Strategies to Accelerate the Transformation of Pharmaceutical Industry... The entire report is available…
On the one hand, you hate to see talent leaving the US. But, you have to applaud their attitude: "Although we are comfortable in America, we often felt that something…
As FiercePharma correctly points out, GSK's Q II report reflects the overall industry trends quite accurately: The rest of Glaxo's report, like the rest of Big Pharma's Q2 results so…
There has been a lot of commentary this week on Pfizer's announcement that their highly respected research center in Sandwich, UK, will be closed. The original press release suggested that…
There is a lot of good commentary and analysis of last week's JP Morgan Healthcare conference, most notably here, here, and here. Here are a few of our thoughts as…
The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil,…
Earlier this week we wrote about the emerging trend of increasing state government involvement in the pharmaceutical industry. Today we learn about what the government in Brazil is doing. Of…